d-Cycloserine adjuvant therapy to conventional neuroleptic treatment in schizophrenia: an open-label study

N. G. Cascella, F. Macciardi, C. Cavallini, E. Smeraldi

Research output: Contribution to journalArticlepeer-review

Abstract

D-cycloserine, a partial agonist at the strichnine-insensitive glycine site of the NMDA receptor complex, was tested as adjuvant treatment to conventional neuroleptics in chronic schizophrenic volunteers. The drug was administered, o.a.d., at the daily dose of 250 mg for six weeks. Mental status outcome measures were completed at the end of each week of treatment. The major finding was a deteriora of the patients' clinical condition, specifically of their psychotic symptoms. These preliminary results are discussed among others in view of d-cycloserine pharmacologic properties and recent findings on the interaction between NMDA agonists and dopamine system. This study, finally, suggests the need for a controlled dose-finding trial to establish the activity and a therapeutic "window" of this drug in schizophrenia.

Original languageEnglish (US)
Pages (from-to)105-111
Number of pages7
JournalJournal of Neural Transmission
Volume95
Issue number2
DOIs
StatePublished - Jun 1994
Externally publishedYes

Keywords

  • cycloserine
  • glycine
  • NMDA receptor
  • PCP-psychosis
  • schizophrenia

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology
  • Psychiatry and Mental health
  • Biological Psychiatry

Fingerprint Dive into the research topics of 'd-Cycloserine adjuvant therapy to conventional neuroleptic treatment in schizophrenia: an open-label study'. Together they form a unique fingerprint.

Cite this